Targeting CAR NK Cells Combined With Immunomodulators Is A Promising Novel Therapeutic Strategy For Ewing Sarcoma

While our bodies have built-in defense cells called Natural Killer (NK) cells that are naturally great at destroying cancer, Ewing sarcoma tumors are notoriously good at defending themselves. The area immediately surrounding these tumors acts like a protective shield that actively shuts down incoming NK cells using a suppressive protein called TGF-beta. It also makes it incredibly hard for the immune cells to locate the tumor or survive long enough to fight back, which is why this cancer is so difficult to treat if it returns or spreads.

To break through this defense, scientists engineered a “super” version of these Natural Killer cells and paired them with a clever multi-pronged treatment. First, they equipped the NK cells with a microscopic homing device—called a Chimeric Antigen Receptor (CAR)—to target a specific protein found on the tumor cells. Next, they “pre-trained” these cells so they become completely immune to the tumor’s shutdown signals. Finally, they combined these upgraded cells with an antibody that acts like a flashing beacon to mark the cancer, alongside an immune-boosting drug to keep the fighter cells alive and active. In laboratory tests, this triple-threat approach successfully shrank tumors and blocked the cancer from spreading to the lungs, opening up an exciting new avenue for treating tough solid tumors.

Read the full article